As part of new grant projects, the Laboratory of Lymphoma Tumor Biology, based in the modern BIOCEV scientific center, is seeking talented and motivated candidates for PhD studies. The laboratory offers a unique opportunity to engage in cutting-edge lymphoma research within an environment that brings together leading scientists from the Czech Academy of Sciences and Charles University.

PhD students will learn a wide range of modern laboratory and bioinformatic techniques, have the opportunity to apply for their own grants, and publish results in prestigious international journals. Research topics cover both basic and preclinical studies, providing a comprehensive perspective on lymphoma biology.

Offered topics:

Molecular mechanisms of B-cell receptor signaling in EZB diffuse large B-cell lymphoma

- The main focus of the project is to determine how somatic genetic alterations affect B-cell receptor signaling in the most common type of lymphoma. Based on literature and our preliminary data, it is assumed that these alterations influence the dynamics of cortical actin and related B-cell receptor signaling.

Multicombinatorial vertical inhibition of the PI3K/AKT signaling pathway in B-cell lymphomas

- The proposed dissertation project focuses on basic research into the molecular mechanisms of multicombination vertical inhibition of the PI3K/AKT signaling pathway in B-cell lymphomas. The project builds on previous results from our research group, which showed that simultaneous inhibition of multiple regulatory levels of the PI3K/AKT pathway leads to more stable signaling inhibition than inhibiting individual members of the pathway.

Treatment of lymphomas using organoid models without the use of chemotherapeutics

- The proposed project aims to develop innovative chemo-free therapeutic strategies through organoid in vitro models that faithfully mimic the complex interactions between tumor cells and their microenvironment. These interactions cannot be explored in detail in conventional 2D cell models, which significantly limits the current understanding of the molecular mechanisms of lymphomagenesis and therapeutic resistance.

Development of new approaches to assess the cellular toxicity of nanomaterials and nano-bio interactions with a focus on regulated forms of cell death

- Nanotechnology is a rapidly developing field with potential in cancer treatment. The aim of the project is to develop new approaches to assess the toxicity of nanomaterials and nano-bio interactions based on identifying their ability to induce various forms of regulated cell death (apoptosis, erythrocytosis, necrosis, ferroposis, pyroposis, etc.) with subsequent testing of the therapeutic applicability of the most promising nanomaterials.

We offer work in a friendly environment within a dynamic group with established international cooperation, operating in a modern scientific center with first-class research facilities. As part of your studies, you will have the opportunity to complete a 6-12 month internship abroad.

Fully funded positions are available with an expected start date in the 2026/2027 academic year.

If you are interested, please send your CV and a short summary of why you would be interested in working in our group to the following email address: ondrej.havranek@lf1.cuni.cz.

The Hematology Laboratories of the First Faculty of Medicine, Charles University at BIOCEV have an opening for a Postdoctoral Fellow in Hemato-Oncology.

For more information click HERE

http://stopka-lab.lf1.cuni.cz

The well-established Laboratory Consortium for Research in Haematooncology and Stem Cells, under the leadership of Prof. Tomáš Stopka, announces a call for 2 candidates for PhD studies. The laboratories are located in BIOCEV - a scientific centre of excellence in biotechnology and biomedicine equipped with state-of-the-art instruments and facilities, which brings together top teams of erudite scientists from institutes of the Czech Academy of Sciences and two faculties of Charles University.

Two PhD projects have been announced:

1. the Leukaemia Research Project, which aims to identify tumour-specific genetic, proteomic and metabolic mechanisms that lead to the development of resistance and failure of anticancer therapy. The student will develop expertise in transformed cell culture, tumour growth in a mouse model, use of primary patient samples, multi-omics techniques and their integration. This will result in futuristic insight into the molecular pathways that determine the resistant phenotype of cancer cells. The PhD project will be carried out in close contact with the 1st Internal Medicine Clinic of the General University Hospital in Prague and the Czech Centre for Phenogenomics in Biocev.

2. The project focuses on Epigenetics in Stem Cells with the aim to understand the establishment of expression profile in differentiating progenitors at the level of DNA remodelling in chromatin. The broader goal is to understand the mechanisms involved in the development, growth and maintenance of tissue-specific stem cells and progenitors throughout the life of the organism. The successful candidate will generate and utilize transgenic animal models with mutations in regulators of chromatin remodelling and high-throughput methods to identify the localization of chromatin remodelling sites and transcription factor binding sites throughout the genome that influence the repression and activation of transcription factor pathways and their transcriptional targets required for normal and tumour development.

The deadline for applications is December 15, 2022 with a start date of early March 2023.

Contacts: Project 1: (kristyna.pimkova@lf1.cuni.cz , stopka@lf1.cuni.cz ) and for Project 2: (juraj.kokavec@lf1.cuni.cz , stopka@lf1.cuni.cz )